Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol.
Journal
NPJ breast cancer
ISSN: 2374-4677
Titre abrégé: NPJ Breast Cancer
Pays: United States
ID NLM: 101674891
Informations de publication
Date de publication:
2019
2019
Historique:
received:
17
09
2018
accepted:
05
02
2019
entrez:
25
4
2019
pubmed:
25
4
2019
medline:
25
4
2019
Statut:
epublish
Résumé
Dedicated breast positron emission tomography (dbPET) is an emerging technology with high sensitivity and spatial resolution that enables detection of sub-centimeter lesions and depiction of intratumoral heterogeneity. In this study, we report our initial experience with dbPET using [F-18]fluoroestradiol (FES) in assessing ER+ primary breast cancers. Six patients with >90% ER+ and HER2- breast cancers were imaged with dbPET and breast MRI. Two patients had ILC, three had IDC, and one had an unknown primary tumor. One ILC patient was treated with letrozole, and another patient with IDC was treated with neoadjuvant chemotherapy without endocrine treatment. In this small cohort, we observed FES uptake in ER+ primary breast tumors with specificity to ER demonstrated in a case with tamoxifen blockade. FES uptake in ILC had a diffused pattern compared to the distinct circumscribed pattern in IDC. In evaluating treatment response, the reduction of SUV
Identifiants
pubmed: 31016232
doi: 10.1038/s41523-019-0107-9
pii: 107
pmc: PMC6467896
doi:
Types de publication
Case Reports
Langues
eng
Pagination
12Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Eur J Cancer. 2011 Sep;47(14):2084-90
pubmed: 21737257
N Engl J Med. 1978 Jun 1;298(22):1223-8
pubmed: 651963
J Clin Oncol. 2001 Jul 15;19(14):3357-66
pubmed: 11454883
Breast Cancer Res Treat. 2016 Feb;155(3):463-9
pubmed: 26820652
N Engl J Med. 2018 Jul 12;379(2):191-192
pubmed: 29996081
N Engl J Med. 2015 Nov 19;373(21):2005-14
pubmed: 26412349
Cell. 1998 Dec 23;95(7):927-37
pubmed: 9875847
EJNMMI Res. 2017 Dec 19;7(1):100
pubmed: 29260333
Clin Breast Cancer. 2017 Jun;17(3):e155-e159
pubmed: 28110902
J Clin Oncol. 2001 May 15;19(10):2596-606
pubmed: 11352951
Cancer. 1977 Jun;39(6 Suppl):2934-47
pubmed: 326386
Breast Cancer Res. 2015 Jul 11;17:94
pubmed: 26163296
IEEE Trans Med Imaging. 1982;1(2):113-22
pubmed: 18238264
AJR Am J Roentgenol. 2005 Jun;184(6):1774-81
pubmed: 15908529
NPJ Breast Cancer. 2019 Apr 16;5:12
pubmed: 31016232
J Clin Invest. 2011 Oct;121(10):3810-8
pubmed: 21965338
Med Phys. 2012 Sep;39(9):5393-404
pubmed: 22957607
Radiographics. 2016 Mar-Apr;36(2):481-96
pubmed: 26963458
Anticancer Res. 1997 May-Jun;17(3B):1573-6
pubmed: 9179196
Lancet Oncol. 2013 Oct;14(11):e465-e475
pubmed: 24079874
J Nucl Med. 2011 Oct;52(10):1541-9
pubmed: 21903739
Eur J Radiol. 2015 Jan;84(1):158-162
pubmed: 25467224
J Clin Oncol. 2006 Jun 20;24(18):2793-9
pubmed: 16682724
J Nucl Med. 2017 Apr;58(4):563-568
pubmed: 27688475
Magn Reson Insights. 2013 Apr 30;6:33-49
pubmed: 25114543
Nat Commun. 2014 Jun 03;5:4006
pubmed: 24892406
J Nucl Med. 1984 Nov;25(11):1212-21
pubmed: 6092569
Lancet. 2014 Jul 12;384(9938):164-72
pubmed: 24529560
Semin Ultrasound CT MR. 2010 Dec;31(6):496-505
pubmed: 21147377
Nucl Med Commun. 2014 May;35(5):446-52
pubmed: 24686195
Br J Cancer. 2014 Aug 26;111(5):837-42
pubmed: 25003667
AJR Am J Roentgenol. 2016 Jun;206(6):1307-14
pubmed: 27058014